Mindset Pharma to defend against lawsuit filed by Reunion Neurosciences

Mindset disagrees with and denies the allegations set forth from Reunion.

NATCO files generic Olaparib Tablets in USA

Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer

Evive enters license agreement with Acrotech Biopharma to commercialize Ryzneuta in US

Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)

Benvic acquires specialty U.S. compounder Chemres

The ninth acquisition since 2018

Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma

Lonza partners with Israel Biotech Fund to support biologics and small molecules development

The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets

Quality issues force Novartis to suspend production of radioligand therapy medicines

The production suspension impacts commercial and clinical trial supply

Lupin appoints Diana Amador-Toro as Senior Vice President, Global Compliance

Diana is a senior leader with more than 38 years of field experience in U.S. FDA’s Office of Regulatory Affairs (ORA)

Erytech sells U.S. manufacturing facility and enters long-term supply agreement with Catalent

Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction

Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products

As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio